We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+34.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$612M
AUM Growth
+$82.6M
Cap. Flow
+$22.2M
Cap. Flow %
3.63%
Top 10 Hldgs %
69.92%
Holding
102
New
27
Increased
15
Reduced
11
Closed
43

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$17.5M
2
ARWR icon
Arrowhead Research
ARWR
+$10.9M
3
ARGX icon
argenx
ARGX
+$6.1M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.71M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.57M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$14.7M
2
ZGNX
Zogenix, Inc.
ZGNX
+$12M
3
PDSB icon
PDS Biotechnology
PDSB
+$8.84M
4
EVH icon
Evolent Health
EVH
+$5.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 61.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
26
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$3.44M 0.56%
203,300
+192,300
+1,748% +$2.91M
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.07M 0.5%
100,000
-55,000
-35% -$1.53M
FENC icon
28
Fennec Pharmaceuticals
FENC
$333M
$3.02M 0.49%
250,000
– –
ARMO
29
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
$2.99M 0.49%
+80,000
New +$3.36M
NBRV
30
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.81M 0.46%
2,239
-81
-3% -$120K
UTHR icon
31
PUT
United Therapeutics
UTHR
$25.7B
$2.81M 0.46%
+25,000
New +$3.18M
VIVE
32
DELISTED
VIVEVE MED INC
VIVE
$2.51M 0.41%
685
+252
+58% +$1.1M
EDIT icon
33
PUT
Editas Medicine
EDIT
$407M
$1.82M 0.3%
55,000
+15,000
+38% +$534K
AERI
34
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$1.63M 0.27%
+30,000
New +$1.68M
RMTI icon
35
PUT
Rockwell Medical
RMTI
$28.5M
$1.59M 0.26%
2,773
-1,227
-31% -$774K
NTLA icon
36
PUT
Intellia Therapeutics
NTLA
$1.5B
$1.58M 0.26%
+75,000
New +$1.84M
QTTB icon
37
Q32 Bio
QTTB
$450M
$1.48M 0.24%
+4,389
New +$1.48M
TWTR
38
CALL
DELISTED
Twitter, Inc.
TWTR
$1.45M 0.24%
+50,000
New +$1.47M
RARX
39
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.43M 0.23%
+270,000
New +$1.93M
TSRO
40
CALL
DELISTED
TESARO, Inc.
TSRO
$1.43M 0.23%
+25,000
New +$1.61M
BEAT
41
DELISTED
BioTelemetry, Inc.
BEAT
$1.24M 0.2%
+40,000
New +$1.32M
AXDX
42
CALL
DELISTED
Accelerate Diagnostics
AXDX
$1.14M 0.19%
+5,000
New +$1.31M
AMPE
43
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.1M 0.18%
+1,083
New +$907K
AMAG
44
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$1.01M 0.16%
50,000
-82,500
-62% -$1.4M
ALIM
45
DELISTED
Alimera Sciences
ALIM
$1M 0.16%
64,955
– –
SGMO
46
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$950K 0.16%
+50,000
New +$1.07M
NVTR
47
DELISTED
Nuvectra Corporation Common Stock
NVTR
$869K 0.14%
+66,724
New +$678K
OSUR icon
48
PUT
OraSure Technologies
OSUR
$286M
$845K 0.14%
50,000
-50,000
-50% -$948K
ANIP icon
49
PUT
ANI Pharmaceuticals
ANIP
$1.82B
$833K 0.14%
+14,300
New +$908K
TWTR
50
PUT
DELISTED
Twitter, Inc.
TWTR
$725K 0.12%
+25,000
New +$733K
1
2
3 4 5

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Acuta Capital Partners held 102 positions worth $612M, up 16% from $530M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Acuta Capital Partners deployed $22.2M of net new capital in Q1 2018, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Arrowhead Research: 1,762,206 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 52% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $14.7M trimmed.

  • Acuta Capital Partners's largest Q1 2018 buy was Arrowhead Research: 1,762,206 shares worth $12.7M.
  • Acuta Capital Partners added most to Gyre Therapeutics in Q1 2018, an estimated $17.5M increase.
  • Acuta Capital Partners's biggest Q1 2018 reduction was Immunomedics Inc, cutting an estimated $14.7M.
  • Acuta Capital Partners fully exited Zogenix, Inc. in Q1 2018, selling an estimated $12M.
  • Acuta Capital Partners's ten largest holdings make up 70% of its $612M portfolio in Q1 2018.
  • Acuta Capital Partners opened 27 new positions and closed 43 in Q1 2018.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $612M.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.